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The sphingolipids ceramide (Cer), sphingosine-1-phosphate (S1P), sphingosine (Sph),
and ceramide-1-phosphate (C1P) are key signaling molecules that regulate major
cellular functions. Their roles in the retina have gained increasing attention during
the last decade since they emerge as mediators of proliferation, survival, migration,
neovascularization, inflammation and death in retina cells. As exacerbation of these
processes is central to retina degenerative diseases, they appear as crucial players in
their progression. This review analyzes the functions of these sphingolipids in retina
cell types and their possible pathological roles. Cer appears as a key arbitrator in
diverse retinal pathologies; it promotes inflammation in endothelial and retina pigment
epithelium (RPE) cells and its increase is a common feature in photoreceptor death
in vitro and in animal models of retina degeneration; noteworthy, inhibiting Cer synthesis
preserves photoreceptor viability and functionality. In turn, S1P acts as a double edge
sword in the retina. It is essential for retina development, promoting the survival
of photoreceptors and ganglion cells and regulating proliferation and differentiation
of photoreceptor progenitors. However, S1P has also deleterious effects, stimulating
migration of Müller glial cells, angiogenesis and fibrosis, contributing to the inflammatory
scenario of proliferative retinopathies and age related macular degeneration (AMD). C1P,
as S1P, promotes photoreceptor survival and differentiation. Collectively, the expanding
role for these sphingolipids in the regulation of critical processes in retina cell types and
in their dysregulation in retina degenerations makes them attractive targets for treating
these diseases.
Keywords: ceramide, sphingosine-1-phosphate, sphingosine, ceramide-1-phosphate, photoreceptor, glia,
pigmented epithelium
Abbreviations: AMD, age related macular degeneration; C1P, ceramide-1-phosphate; Cer, ceramide; CerK, ceramide kinase;
CerKL, Cer kinase-like; CerS, Cer synthase; CERT, Cer transport protein; DAMP, damage associated molecular pattern;
DHA, docosahexaenoic acid; DHCer, dihydroceramide; ER, endoplasmic reticulum; GDNF, glial derived neurotrophic factor;
GlucoCer, glucosylceramide; OS, outer segments; PARP1, poly ADP-ribose-polymerase 1; PUFA, polyunsaturated fatty acids;
ROS, reactive oxygen species; RPE, retinal pigment epithelium; S1P, sphingosine-1-phosphate; S1PR, S1P receptor; SM,
sphingomyelin; SMase, sphingomyelinase; Sph, sphingosine; SphK, sphingosine kinase; SPP, S1P phosphatases; SPT, serine
palmitoyltransferase; TNF, tumor necrosis factor; VLCPUFA, very long chain polyunsaturated fatty acids.
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INTRODUCTION
Sphingolipids entered the group of Bioactive Lipids about
three decades ago; however, they are still regarded by many
as newcomers, less familiar than the phosphatidylinositol
phosphates, prostaglandins or leukotrienes. Yet, the
overwhelming amount of literature accumulated evidences that
simple sphingolipids such as Cer, Sph, and their phosphorylated
derivatives, S1P and C1P (Figure 1) have taken centre stage
in controlling normal and pathological cellular processes
throughout the organism.
First identified in the brain by Thudichum in the late
19th century, for virtually another century their functions
remained as enigmatic as the Sphinx their name honors. Being
lipid molecules, they were considered as ubiquitous membrane
components both in animal and plant cells for several decades.
Even just as such, they have multiple and relevant roles. They are
crucial constituents of lipid rafts and regulate their formation and
expansion, essential for building signaling platforms (Grassme
et al., 2001); they are also critical for receptor function, membrane
conductance and cell–cell interactions, and play key roles in
pathogen internalization (Huwiler et al., 2000; Gulbins and
Kolesnick, 2003; Hannun and Luberto, 2004). The pioneer work
from both Hannun and Kolesnick laboratories three decades ago
added an additional dimension to their biological relevance; the
groundbreaking findings that Sph inhibits protein kinase C and
Cer is a “potential second messenger” in the signaling cascade
activated by TNF-α provided the first data as to their role as
bioactive lipids (Hannun et al., 1986; Kolesnick, 1987; Dressler
et al., 1992; Obeid et al., 1993). Sph and Cer were then established
to inhibit cell growth and promote cell death upon different
cell stressors. The family of bioactive sphingolipids gained in
complexity when their phosphorylated counterparts, S1P and
C1P were shown to control the opposing processes, proliferation
and cell survival. The sphingolipid family also includes GlucoCer,
lactosylceramide, several gangliosides and DHCer.
These bioactive lipids respond to a diversity of cell stimuli
by modifying their intracellular levels, thus regulating multiple
signaling pathways that finally induce major changes in cell fate.
Their roles have strikingly extended to include virtually every
aspect of cell biology, from cell cycle, differentiation, endosome
and exosome formation, adhesion and migration to angiogenesis,
immune response, inflammation and cell death, including
autophagy and apoptosis. Recent advances have revealed that
sphingolipid mediators play important roles in human disease.
This Review focuses on the functions played by simple
sphingolipids in the retina during development and particularly
in the onset of retina pathologies. Lipids have long been
known to be essential for maintaining both the structure
and functionality of the visual system. Docosahexaenoic acid
(DHA) has been shown to promote photoreceptor survival and
differentiation, and docosanoids, such as Neuroprotectin D1,
and elovanoids have relevant neuroprotective roles in the retina
(Rotstein et al., 1996, 1997; Jun et al., 2017; Bazan, 2018).
Conversely, mutations of lipid metabolizing proteins and chronic
misregulation of retinal lipid metabolism have been linked to
retinal degeneration (Fliesler and Bretillon, 2010; Friedman et al.,
2010; Yu et al., 2011). During the last decade, understanding on
the relevance of lipids in the retina has expanded to reveal the
involvement of sphingolipids in numerous ocular diseases. Here,
we briefly present the structural characteristics and metabolism
of sphingolipids and a concise description of the physiological
and pathophysiological roles of simple sphingolipids as Cer, Sph,
S1P, C1P, and DHCer. We then focus on the information that
points to both their deleterious and protective functions in the
retina and in retina pathologies, supporting the emerging roles of
sphingolipids as novel mediators in retina degenerative diseases.
Structure and Metabolism of
Sphingolipids
The sphingolipid family encompasses a huge diversity of
molecular species that place them among the major lipid classes
in eukaryotic cells. Sph, a straight, long chain (18–20 carbon
atoms) aminoalcohol, is the common backbone shared by all
these species (Figure 1). Attachment of a fatty acid to Sph
through an amide bond gives rise to Cer, the central molecule in
sphingolipid metabolism (Fahy et al., 2005). Further attachment
of hundreds of diverse headgroups at the C-1 position of
Cer originates the more complex sphingolipids (Figure 1).
Taking into account than in addition to these huge number of
headgroups, sphingolipids are formed by at least sixty different
long-chain bases and dozens of fatty acids varying from twelve
to over thirty carbons in length, the number of sphingolipid
molecular species is likely in the tens of thousands (Merrill et al.,
1993). If we add this up to their complex metabolism, and their
ability to interconvert upon different and even opposing cell
stimuli, we can start to grasp their extraordinary flexibility for
modulating an ample range of cell responses.
A key to the multiplicity and diversity of the signaling roles
of sphingolipids is in their intricate and highly interconnected
metabolism, their constant cross-conversions that modify their
levels upon changes in the environment (Figure 2). Cer is
the central hub among these metabolic pathways and can be
synthesized by different pathways, de novo synthesis, degradation
of sphingomyelin (sphingomyelinase pathway) and recycling of
Sph and complex sphingolipids (salvage pathway). De novo
synthesis begins in the ER (Mandon et al., 1992) with the
condensation of L-serine and palmitoyl CoA, catalyzed by SPT;
the resulting 3-ketosphinganine is reduced to sphinganine, which
is amino-acylated with a chain of 14 to 32 carbons to form diverse
DHCer species; finally, the insertion of a trans double bond at the
C4 position of the sphingoid base backbone by DHCer desaturase
gives rise to Cer. SPT, a heteromeric complex, is responsible for
opening the entrance to the sphingolipid network. Interestingly,
recent evidence has uncovered that subunit mutations causing
hereditary sensory and autonomic neuropathy type 1 (HSAN1)
shift SPT preference to use alanine and glycine instead of serine
(Penno et al., 2010; Bode et al., 2016). This gives rise to a class of
atypical 1-deoxysphingolipids, such as deoxy(dihydro)ceramides
and 1-deoxysphingosine, shown to induce cell death in various
cell types. When elevated, as in HSAN1, they are neurotoxic and
contribute to sensory and autonomic neuropathies affecting both
cytoskeletal stability, NMDA receptor signaling and membrane
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FIGURE 1 | Chemical structures of sphingolipid molecules. The structures of different sphingolipid types are shown. All sphingolipids share a sphingosine backbone
(black). This sphingoid backbone is amide-linked to a fatty acid moiety (blue).
FIGURE 2 | The sphingolipid network: metabolic interconnection between bioactive sphingolipids. Ceramide, the central hub of sphingolipid metabolism, is
synthesized by the de novo pathway (light blue), from serine and palmitoyl CoA, by the sphingomyelinase pathway, i.e., through hydrolysis of sphingomyelin
mediated by sphingomyelinases (SMase) (orange) or by the salvage pathway (green). Ceramide can then be phosphorylated to generate Ceramide-1-phosphate
and/or deacylated to form sphingosine, which is then phosphorylated to generate sphingosine-1-phosphate (S1P). The catabolism of S1P mediated by S1P lyase
provides the only exit route from the sphingolipid network. CDase, ceramidase; CERK, ceramide kinase; GCase, glucosylceramidase; SMase, sphingomyelinase; SM
synthase, sphingomyelin synthase; SphK, sphingosine kinase; SPPase, sphingosine phosphate phosphatase. The inhibitors mentioned in this Review are indicated
in red.
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properties (Jiménez-Rojo et al., 2014; Güntert et al., 2016). SPT
can also change its selectivity for palmitate, using myristate or
stearate as substrates (Hornemann et al., 2009; Harmon et al.,
2013), further increasing the diversity of sphingolipid molecules.
The newly synthesized Cer can be glycosylated by GlucoCer
synthase on the cytoplasmic surface of the Golgi, to render
GlucoCer, the precursor of glycosphingolipids, or galactosylated
by galactosyl Ceramide synthase in the ER (Figure 2; Raas-
Rothschild et al., 2004). It can also receive a phosphocholine
head group from phosphatidylcholine and thus generate
sphingomyelin (SM), a reaction mediated by SM synthases
(Tafesse et al., 2006). In turn, these complex sphingolipids
can generate Cer through basal or signal-mediated catabolic
pathways. The hydrolysis of the phosphodiester bonds in SM,
catalyzed by at least five different SMases, renders Cer through the
so-called sphingomyelinase pathway (Figure 2). These enzymes
present several isoforms differing in subcellular localization,
optimal pH range and cation dependence. A prominent example
is neutral SMase; a Mg2+ -dependent form is localized in the
plasma membrane whereas a cation-independent form is found
in cytosol (Marchesini and Hannun, 2004); a mitochondrial
neutral SMase has also been identified (Wu et al., 2010;
Rajagopalan et al., 2015). The acid SMase gene can also
generate, through differential trafficking, a cation-independent
acid SMase, found in the endosomal-lysosomal compartment
and an acid SMase that is secreted extracellularly and is
responsible for hydrolyzing SM in the outer leaflet of the
plasma membrane in addition to that present in plasma
lipoproteins (Jenkins et al., 2009). Activation of SMases
in response to diverse stimuli in different compartments
provides the means for a rapid Cer generation, crucial for
signal transduction.
A third pathway for Cer generation relies on the breakdown
of complex sphingolipids in the lysosomal or late endosomal
compartment through the reverse activity of different hydrolases,
such as specific β-glucosidases and galactosidases, to form
Cer, which cannot be released from this compartment. The
subsequent activity of at least five different ceramidases generates
Sph and its recycling in the ER and reacylation by CerSs
yields Cer; this “salvage pathway” (Figure 2) is involved in
inflammatory processes (Kitatani et al., 2008; Canals et al.,
2018). Finally, exogenous Cer can also be recycled and generate
endogenous Cer by the reverse action of ceramidases (Kitatani
et al., 2008; Novgorodov et al., 2011).
Cer is phosphorylated by a specific kinase, CerK to form
C1P (Wijesinghe et al., 2005). As stated above, deacylation
of Cer by ceramidases renders Sph, the phosphorylation of
which by one of the two existing SphKs, SphK1 and SphK2,
generates S1P (Hait et al., 2006; Figure 2). The irreversible
degradation of S1P by S1P lyase, at the cytoplasmic side
of the ER, yields ethanolamine-1-phosphate and hexadecenal,
providing the only release gate from the complex sphingolipid
metabolic cycle (Bandhuvula and Saba, 2007). Comprehensive
and detailed accounts of sphingolipid molecular diversity and
metabolism can be found in excellent previous reviews (Lahiri
and Futerman, 2007; Kitatani et al., 2008; Hannun and Obeid,
2011; Canals et al., 2018).
To Be or Not to Be. . ., a Decision for the
Sphingolipid Rheostat
By 1995, several seminal findings evidenced that Cer and
S1P had opposing cellular roles; whereas growth and survival
factors increase S1P levels to stimulate proliferation and survival,
different cell stressors promote an intracellular accumulation
of Cer, which arrests the cell cycle or induces cell death.
The ready interconversion of S1P, Sph, and Cer (Figure 2),
prompted by numerous cues that stimulate or inhibit the
activities of the enzymes involved, provides a significant tool
for determining the patterns of intracellular signaling and
deciding the physiological outcome. This understanding led to
the proposal that the opposite functions of S1P and Cer transform
their signal-mediated interconversion in a sensor of intracellular
conditions, and the consequent rapid alteration of the balance
between their levels in a key switch in the control of cell fate, later
termed as the “sphingolipid rheostat” (Gómez-Muñoz et al., 1995;
Cuvillier et al., 1996).
Since then, the collective effort of numerous laboratories
has shed new light on the molecular actors and the signaling
pathways involved in the intricate cross-reactions of these
sphingolipids, included new sphingolipid molecules such as C1P
and DHCer, and shown that this rheostat is involved in the
induction of multiple pathologies, including neurodegeneration
(Taha et al., 2006; Hannun and Obeid, 2008; Young et al.,
2013; Newton et al., 2015; Wang and Bieberich, 2018). The
extensive available data provides us with an optimal position
to complete the unraveling of the sphingolipid universe. The
subcellular compartmentalization of their metabolic pathways
has been established and the major enzymes giving rise
to this diversity of sphingolipids have been identified and
cloned during the past three decades. New evidence suggests
that different Cer molecular species, generated by different
pathways in different compartments might differ in their
intracellular roles (Hannun and Obeid, 2011; Hernández-
Corbacho et al., 2015). Hence, the relevance of the sphingolipids
involved in the rheostat model extends beyond their relative
levels and the tightly regulated enzymes involved in their
synthesis and degradation to encompass the innumerable and
frequently opposite signaling pathways they control, their site of
biosynthesis and their release to the extracellular milieu, to finely
tune the sphingolipid rheostat.
Sphingolipids in Eye Pathology
The last 15 years have seen the buildup of a body of evidence
pointing to a role for sphingolipids in normal development
and function of the retina and in the pathogenesis of ocular
diseases. The first link between alterations in sphingolipid
metabolism and eye disease originated from lysosomal storage
diseases, collectively denominated sphingolipidoses, which arise
in mutations in the enzymes or cofactors involved in sphingolipid
degradation. These diseases share an early neurodegeneration
and visual impairment, with ocular manifestations including
retinal vascular abnormalities, degeneration of ganglion cells, and
even blindness (Harcourt and Ashton, 1973; Brownstein et al.,
1978; Brownstein et al., 1980; Chen et al., 2014).
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In Farbert’s disease, Cer accumulation in the retina brings
on visual dysfunction, with ganglion cells being the most
affected (Zarbin et al., 1988). Brain accumulation of Cer
occurs in the juvenile form of Batten disease, in which retina
neurodegeneration and blindness are early events (Puranam
et al., 1997). These early reports underscored the relevance of
sphingolipid metabolism in eye pathogenesis; however, few clues
existed on how this accumulation led to ocular manifestations.
Thrillingly, work from many laboratories over the last decade
has implicated sphingolipids such as Cer, S1P, Sph, and C1P in
the progression of ocular diseases, including diabetic retinopathy,
retinitis pigmentosa, AMD and other neuronal degenerative
diseases. We will first summarize the sphingolipid species present
in the eye and then review their roles in retinal cells and in the
pathogenesis of these diseases.
Sphingolipid Presence in the Eye
Due to their high complexity, detailed composition analysis of
retina sphingolipids is quite recent. Sphingolipids amount to
about 11–13 (mole) % of both rat and bovine retinal lipids (Brush
et al., 2010). SM is the most abundant species, amounting to 2.4–
2.5% of total retinal lipids, whereas Cer and GlucoCer amount
to less than 1%. Retinal sphingolipids have abundant (nearly
90%) of saturated, and particularly very long chain saturated fatty
acids, with 18:0 and 16:0 being the most abundant fatty acid
species. They contain about 2–3% of DHA, 22:6 n–3, the most
abundant PUFA, but no VLCPUFA longer than 24 carbons are
present (Brush et al., 2010); this is intriguing since the retina is
characterized for the abundance of PUFA and VLCPUFA, which
are enriched in sphingolipids in other tissues (Aveldaño and
Sprecher, 1987; Oresti et al., 2011). In mice retina, almost 80% of
Cer contains 16:0 and 18:0, with 21% having 20:0 or longer chain
fatty acids (Fox et al., 2006). Bovine rod OS have lower levels
of sphingolipids than the whole retina, varying from 3.4 to 6.4
mole % (Brush et al., 2010). SM and Cer from detergent resistant
membranes obtained from rod OS are enriched in saturated fatty
acids (Martin et al., 2005).
Diverse studies confirm the earlier observations that the
sphingolipid profile is modified in retinal pathologies. Cer mass
content decreases in retinas from diabetic mice compared to
normal retinas, without modifying its fatty acid composition,
with a concomitant increase in GlucoCer, and no changes in
Sph and SM (Fox et al., 2006). The relevance of particular
Cer molecular species in preserving retinal functions has been
emphasized by recent findings from the Busik laboratory,
demonstrating that overexpression of elongation of very long-
chain fatty acids protein 4 (ELOVL4), whose presence is
significantly reduced in the diabetic retina, preserves tight
junctions and prevents retinal vascular permeability; this effect
is parallel to an increase in the levels of Cer having 16 and 24
carbons, and very long chain fatty acids, which localize in and
might stabilize tight junctions (Kady et al., 2018). In a retinitis
pigmentosa model, the 23H-1 rat, photoreceptor degeneration
starts at the beginning of light responsiveness; Cer, S1P and SM
increase in the retina early during degeneration, with a reduction
in shorter-chain species and an increase in longer-chain species
(Stiles et al., 2016).
The fact that sphingolipids are affected during the course of
degeneration intuitively makes them likely candidates to have
a role in retinal diseases. A combination of studies in vivo and
in vitro has contributed to our understanding of these roles.
In vivo studies with animal models have provided comprehension
on the biological functions of sphingolipids and allowed to test
the physiological effects of modulating its levels. Research in vitro
has allowed dissecting their specific effects on particular cell
types and the biochemical pathways involved in these effects.
We will now highlight the findings that support that significance
of sphingolipids during normal development and in pathologies
affecting the retina.
CERAMIDE, A CRUCIAL EXECUTIONER
IN RETINAL DEGENERATION
Cer Metabolism
Cer has a central role in the sphingolipid family, both structural
and metabolic. Consisting in a Sph molecule bound to a fatty
acid of 16 to 24 carbons length (Fahy et al., 2005), these long
acyl chains confer Cer its high hydrophobic properties; unable
to exist in a free-solution form in the cytoplasm, it is the most
hydrophobic lipid in biological membranes (Castro et al., 2014).
This apparently static, membrane-confined location of Cer does
not preclude it from having key intracellular actions, as the
regulation of cell cycle and cell death.
As Cer is synthesized in the ER, its hydrophobic nature
demands a transport mechanism to reach its diverse cellular
destinations. Cer transport to the trans Golgi region, to generate
SM, involves a CERT, which carries it in a non-vesicular manner
(Hanada et al., 2009). Cer has very different patterns of tissue
distribution and functions (Bartke and Hannun, 2009; Kurz
et al., 2018). Interestingly, six specific types of CerSs (CerS
1–6) have been identified, each of them attaching acylCoAs
differing in their chain length to the sphingoid backbone, thus
generating different molecular species of Cer, with distinct
cellular effects (Levy and Futerman, 2010; Park and Pewzner-
Jung, 2013; Wegner et al., 2016). The distribution of these CerSs
differs between organs and even between cell types in the same
organ, contributing to a characteristic Cer composition (Laviad
et al., 2008; Kremser et al., 2013).
Ceramide Biological Functions
Numerous cellular stressors, such as oxidative stress, absence
of trophic factors, chemotherapy, and UV radiation, activate
the synthesis of Cer; the consequent increase in Cer levels
mediates many cell-stress responses, including the regulation
of cell growth, differentiation (Okazaki et al., 1989), senescence
(Trayssac et al., 2018), proliferation, necrosis, apoptosis and
autophagy (Obeid et al., 1993; Hannun and Obeid, 2008;
Scarlatti et al., 2004). These multiple roles of Cer result
from its ability to act both at membrane level and as an
intracellular messenger. Cer is a key modulator of membrane
dynamics; as a cone-shaped lipid, it readily forms non-lamellar
phases with increased negative spontaneous curvature, thus
promoting membrane invagination, budding and fusion
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 June 2019 | Volume 13 | Article 246
fncel-13-00246 June 11, 2019 Time: 15:42 # 6
Simón et al. Sphingolipids in Retinal Degeneration
(Holopainen et al., 2000; Stancevic and Kolesnick, 2010). Cer
initiates multiple signaling pathways through the rapid formation
or expansion of Cer-enriched microdomains in the plasma or
outer mitochondrial membrane. These microdomains allow for
the interaction and/or oligomerization of different proteins, such
as death receptors in the former or Bax in the later that then
signal the activation of diverse death programs (Grassmé et al.,
2001; Ganesan et al., 2010).
In addition, Cer triggers many of its effects by acting as a lipid
second messenger, through the activation of several intracellular
targets. Cer activates protein phosphatase PP1A and PP2A
(Chalfant et al., 1999) and regulates protein kinase C zeta (PKCζ)
and Akt activity (Wang et al., 2005; Canals et al., 2018; Hannun
and Obeid, 2018) as well as raf-1 and the kinase-suppressor of
Ras, significantly changing the level of phosphorylation of various
key substrates (Ruvolo, 2003).
Among the multifaceted roles of Cer, autophagy and cell
death have been those that have drawn more attention. Cer
controls both autophagy-mediated cell survival and cell death by
regulating nutrient transport, ER stress and mitophagy (Dany
and Ogretmen, 2015). Still, Cer has been more frequently
identified as a key cell death player (Galadari et al., 2015),
activating both the intrinsic and extrinsic pathways of apoptosis.
Although its actual contribution to the apoptotic response in
living cells has been unclear, multiple in vitro studies suggest that
Cer might initiate cell death by acting directly on mitochondria.
In an interesting recent work, a diverting CERT-mediated
Cer transport to mitochondria has been shown to trigger
Bax-dependent apoptosis (Jain et al., 2017).
Knowledge on the role of Cer in different pathological
processes is vast and constantly expanding, and there are
excellent reviews covering its functions (Canals et al., 2018;
Hannun and Obeid, 2018; Kurz et al., 2018). We will here focus
on Cer functions in retinal physiology and pathologies.
Ceramide in the Retina
Cer and Retina Degeneration
Acharya’s group provided the first direct link between Cer
and the death of retinal neurons in a Drosophila model of
retinal degeneration. Using photo-transduction mutants, they
demonstrated Cer has a crucial role in photoreceptor fate;
keeping Cer levels low by preventing its de novo synthesis or by
targeting neutral ceramidase suppresses photoreceptor death in
the Drosophila mutants (Acharya et al., 2003). In functional null
mutants of Drosophila ceramidase, photoreceptors degenerate in
a light-dependent manner, do not respond to light stimulus and
have no effective turnover of rhodopsin; in turn, overexpression
of ceramidase, even in tissues distant from photoreceptors,
suppresses their degeneration in arrestin mutants and facilitates
membrane turnover in a rhodopsin null mutant (Acharya et al.,
2008). Furthermore, a Drosophila mutant in the CerK shows
increased Cer levels leading to the loss of phospholipase C activity
and inhibition of phototransduction, ultimately accompanied by
photoreceptor degeneration (Dasgupta et al., 2009).
Along the last decade, increasing evidence points to a key
involvement of Cer in the onset of retina degeneration in
mammals (Table 1). The gradual loss of photoreceptors observed
in a rabbit model of retinal detachment correlates with the
TABLE 1 | Ceramide and sphingosine functions in the retina.
Sphingolipid Retinal Process
Ceramide (Cer) Photoreceptor death
↓ Cer levels rescues photoreceptors from death in Drosophila RP models (Acharya et al., 2003)
↑ Cer levels induces photoreceptor loss of function and death in Drosophila (Dasgupta et al., 2009)
Photoreceptor death induced by retinal detachment correlated with ↑ Cer levels in rabbits (Ranty et al., 2009)
↓ Cer levels by Myoricin treatment (de novo Cer synthesis inhibitor) rescue photoreceptors in a rd10 mouse model (Strettoi et al., 2010)
↓ Cer levels by inhibiting de novo synthesis with FTY720 delays retinal degeneration in P23H-1 rats (Stiles et al., 2016)
↓expression of acid SMase protects the retina and preserves its function after ischemic injury in an acidic SMase +/− mice model (Fan
et al., 2016)
Intra-vitreal C2Cer injection causes vision loss in rats (Lou et al., 2017)
C2Cer treatment induces photoreceptor and amacrine cell death in rat retinal neuronal cultures (German et al., 2006)
Oxidative stress ↑ Cer levels and leads to cone cell death in 661W cell line (Sanvicens and Cotter, 2006)
Brief C2Cer treatment induces photoreceptor death by activating parthanatos in rat retinal cultures (Prado Spalm et al., 2018)
Retinal Pigment Epithelium (RPE) dystrophy
C2Cer induces caspase-dependent death in rat RPE cells (Tomita et al., 2000)
Oxidative stress ↑ Cer levels and activates cell death in ARPE-19 cells (Sugano et al., 2018)
C2Cer treatment induces apoptosis in non-polarized, but not in polarized RPE cells (Zhu et al., 2010)
Sphingosine (Sph) Photoreceptor death
Oxidative stress ↑ Sph synthesis, preceding the onset of photoreceptor death in vitro (Abrahan et al., 2010)
Addition of exogenous Sph induces mitochondrial-dependent photoreceptor death (Abrahan et al., 2010)
RPE alterations
Increased levels of Sph in SMase knockout mice match with age-dependent retina degeneration and RPE alterations, and an impaired
autophagic flux (Wu et al., 2015)
Overexpression of acid ceramidase in ARPE19 cells ↑ Sph levels and protects these cells from oxidative stress (Sugano et al., 2018).
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production of Cer (Ranty et al., 2009). Intra-vitreal C2-Cer
injection causes vision loss in rats, increasing apoptosis and
expression of glial fibrillary acidic protein, a marker of gliosis
(Lou et al., 2017). A recent work in a mouse model of Farber
disease, with a deficiency in acid ceramidase activity, provides
direct evidence of accumulation of Cer in the retina, associated
to inflammation and severe visual loss (Yu et al., 2018). Ischemia
increases the expression of acid SMase, increasing Cer levels and
leading to retinal degeneration in wild type mice; reduction of
this expression in an acid SMase+/−mouse model decreases Cer
levels, protects retina structure and preserves its function after
ischemic injury (Fan et al., 2016). However, the maintenance of a
basal acid SMase activity is necessary for preserving normal retina
structure and function; a total deficiency in acid SMase, as occurs
in acid SMase knockout mice, leads to the disruption in lysosomal
function and prominent photoreceptor degeneration (Wu et al.,
2015). Mandalt’s group showed alterations in the sphingolipid
profile in P23H-1 rat retinas during degeneration, with an
increase in neutral SMase activity leading to higher Cer levels
at PN22. Treatment with FTY720, an established CerS inhibitor,
partly decreases neutral SMase activity and delays the alterations
in retina structure and functionality, granting partial neuronal
protection. However, this treatment also leads to a stimulation
of acid SMase activity and the consequent increase in Cer
levels, which might explain why FTY720 does not fully prevent
degeneration (Stiles et al., 2016). This underscores the relevance
of establishing not only the pathways leading to Cer increase in
each retinopathy but also whether inhibition of a major pathway
promotes the activation of further biosynthetic paths, to identify
the targets to effectively promote photoreceptor survival.
Diabetic retinopathy is the major cause of blindness among
working age adults; increased Cer levels have been associated
to reduction of insulin action (Chaurasia and Summers, 2015)
and recent research establishes Cer as a relevant player in the
progression of this retinopathy. Acid SMase is highly activated in
the diabetic retina, particularly in retinal endothelium, elevating
Cer levels and contributing to the pro-inflammatory changes in
this tissue; noteworthy, DHA, which is decreased in the diabetic
retina (Tikhonenko et al., 2010), downregulates the expression
of acid SMase in human retinal endothelial cells (Opreanu et al.,
2010; Busik et al., 2012; Hammer and Busik, 2017). Acid SMase
vascular isoform specifically increases in the retinas of diabetic
animal models at the vasodegenerative stage, whereas its absence
or downregulation with DHA prevents capillary formation and
cytokine production (Opreanu et al., 2010, 2011; Busik et al.,
2012; Chakravarthy et al., 2016). Activation of acid SMase and the
consequent Cer increase appear as relevant contributors to the
pathogenesis of diverse retina degenerations, and reestablishing
an adequate balance in sphingolipid levels emerges as essential to
maintain retina functionality.
Ceramide and Photoreceptor Death
The work of several groups, including ours, has provided direct
links between Cer increase and the onset of photoreceptor
death. This death is the hallmark of most retinal degenerative
diseases with very diverse etiologies (Chang et al., 1993;
Portera-Cailliau et al., 1994; Sancho-Pelluz et al., 2008); hence,
uncovering common molecular mechanisms and mediators is
essential to identify new therapeutic targets. In vitro studies
have been fundamental to establish Cer as a mediator of
photoreceptor death. Our group demonstrated that oxidative
stress increases the de novo synthesis of Cer preceding
photoreceptor death in rat retina cultured neurons, whereas
inhibiting this synthesis with fumonisin B1, a CerS inhibitor,
prevents this death (German et al., 2006). These neurons
present low levels of DHA, which has been shown to be
neuroprotective for photoreceptors (Rotstein et al., 1996, 1997).
DHA supplementation protects photoreceptors from C2-Cer
and oxidative stress-induced death, promoting the synthesis
of GlucoCer (German et al., 2006). Cotter’s group extended
Cer role in oxidative stress-induced death of photoreceptors;
they showed that treatment of 661W cells, a cone cell line,
with a nitric oxide donor increases Cer levels by activating
acid SMase; inhibition of Cer synthesis by an acid SMase
inhibitor (Desipramine) prevents cone cell death (Sanvicens
and Cotter, 2006). Interestingly, induction of oxidative stress
with H2O2 also raises Cer levels and promotes cell death
in 661W cells, whereas inhibiting de novo synthesis of
Cer with Myriocin, a serine palmitoyl transferase inhibitor,
prevents Cer increase preserving cell viability (Fabiani et al.,
2017). The buildup of Cer, arising from the activation of
different biosynthetic pathways in rod and cone photoreceptors,
emerges as a death arbitrator in photoreceptors, suggesting
that pharmacological prevention of this increase might have
therapeutic potential (Figures 3, 4).
In vivo studies have supported this hypothesis. Cer levels
increase during the peak of photoreceptor degeneration in
the rd10 mouse, a mouse model of Retinitis Pigmentosa, and
treatment with Myriocin noticeably prevents photoreceptor
loss and preserves both photoreceptor morphology and retina
functionality (Strettoi et al., 2010). Although the genetic
mutations in Retinitis pigmentosa and in animal models of this
disease affect mostly rods, their death is eventually followed by
the death of cones; noteworthy, Myriocin was also effective as a
strategy to promote cone survival in the same rd10 model, even
after rod death (Piano et al., 2013).
Increasing evidence suggests that Cer activates death
pathways alternative to those of canonical apoptosis to
induce photoreceptor demise. Cer increase triggers several
pathways in 661W cells subjected to oxidative stress; it not
only induces the mitochondrial pathway and subsequent
activation of caspases, but also promotes Ca2+ increases in
both mitochondria and cytosol that precede the activation of
calpain-mediated death and activates cathepsin D pathway as
well (Sanvicens and Cotter, 2006).
We have recently established that Cer activates PARP-1
to induce photoreceptor death. Cer induces photoreceptor
death in cultured rat retina neurons in a caspase-independent
process, involving generation of ROS, increase in mitochondrial
permeability, activation of PARP-1 and calpain, accumulation
of poly ADP-ribose polymers and nuclear translocation of
AIF (Prado Spalm et al., 2018), which are features of a
recently unveiled death process named Parthanatos (David
et al., 2009). Notably, inhibition of both PARP-1 and calpain
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FIGURE 3 | Actions of S1P, Cer, and C1P on retinal neurons and RPE cells. This figure summarizes the effects shown for S1P, Cer, and C1P on different retinal
neurons and RPE cells.
activity rescues photoreceptors from Cer-induced death (Prado
Spalm et al., 2018). Paquet-Durandt’s group established PARP-
1 activation as a common non-apoptotic mechanism involved
in retinal neurodegeneration in animal models encompassing
the major groups of inherited human blindness (Arango-
Gonzalez et al., 2014). PARP-1 activity is crucial in the
induction of photoreceptor death in the rd1 and rd2 mouse
models (Sahaboglu et al., 2017). Activation of PARP-1 has
only been associated with Cer-induced death in neuroblastoma
cells (Czubowicz and Strosznajder, 2014); hence, these findings
not only link for the first time Parthanatos with Cer-induced
photoreceptor death but support Parthanatos as a novel cell
death routine triggered by Cer. Although different retinal
neurodegenerative diseases may have particular cell death
mechanisms, taking together these studies Parthanatos appears
as a central, shared photoreceptor death-process with Cer
as a crucial mediator in these degenerations. Targeting Cer
overproduction or Parthanatos key molecular actors might
provide enticing strategies for novel, disease-independent
treatments for retina neurodegenerations.
Cer as a Death Mediator in Other Neuronal Types in
the Retina
Cer role as a mediator in the induction of cell damage is not
confined to photoreceptors. A 24 h treatment with C2-Cer
induces death of amacrine neurons in retina neuronal cultures
(German et al., 2006). Optic nerve crush, which triggers the
injury to retinal ganglion cells in the rat retina, increases the
expression of enzymes involved in Cer biosynthesis (Agudo-
Barriuso et al., 2013). Gene expression profiling in injured retinal
ganglion cells following overexpression of the Sox11 transcription
factor revealed that genes associated with Cer biosynthetic and
metabolic processes are upregulated, suggesting the activation of
a Cer-induced cell death pathway (Norsworthy et al., 2017).
Cer and RPE Degeneration
Cer also plays a pivotal role in diseases affecting RPE function,
such as AMD and Stargardt disease. Atrophy of RPE cells
followed or accompanied by photoreceptor cell death is usually
the final outcome of all forms of retinitis pigmentosa, despite
their different etiologies. RPE atrophy, i.e., RPE cell death, in
the macular region is the primary event in dry AMD and a
common event in early stage wet AMD (Al-Zamil and Yassin,
2017). C2-Cer induces death of human and rat RPE cultured
cells, which involves caspase activation and is partially prevented
by antioxidants and growth factors (Tomita et al., 2000; Kannan
et al., 2004; Sreekumar et al., 2009). Oxidative stress increases
Cer levels and induces apoptosis in human RPE cells and
this was replicated by using C2- and C6-Cer (Barak et al.,
2001). Oxidative stress increases both Cer and hexosyl-Cer
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FIGURE 4 | The relevance of the sphingolipid rheostat in retina photoreceptors. Increases in Cer levels through the activation of its de novo synthesis or the SMase
pathway trigger photoreceptor death; this death is also induced after Cer hydrolysis to increase Sph levels, mediated by ceramidase (CDase). In turn, S1P and C1P
promote photoreceptor survival and differentiation. Docosahexaenoic acid (DHA) promotes survival by regulating the sphingolipid rheostat, inhibiting SMase or
stimulating the synthesis of glucosylceramide (GlucoCer) to decrease Cer levels or enhancing the synthesis of S1P. Exogenous addition of C1P also promotes
photoreceptor survival and differentiation.
levels in ARPE-19 cells, a human RPE cell line, promoting
cell death; this death is prevented by over-expression of acid
ceramidase, which increases Sph levels but not those of S1P
(Sugano et al., 2018). Interestingly, increased serum levels of
hexosyl-Cer have been reported in patients with late stage AMD
(Pujol-Lereis et al., 2018). Noteworthy, oxidative stress leads to
increased S1P levels in control RPE cells, which might reflect
an attempt to counteract Cer action toward cell death (Sugano
et al., 2018). Laser exposure, a frequent treatment for retina
neovascularization, induces human RPE cell death concomitant
with Cer overproduction (Barak et al., 2005).
Cer significance as a mediator of RPE cell death is also
evidenced by the induction of cell death in ARPE19 cells
overexpressing neutral SMase3. Intracellular Cer increase and
cell death are proportional to the amount of the transfected
enzyme and SMase3 overexpression also inhibits proliferation
in ARPE19 cells (Zhu et al., 2010). Intriguingly, C2-Cer
treatment induces apoptosis in non-polarized RPE cells but
does not affect differentiated and polarized RPE cells (Zhu
et al., 2010). This differential susceptibility suggests that while
healthy, polarized cells forming the RPE monolayer in vivo
may be resistant to injures leading to an eventual Cer increase,
non-polarized, activated RPE cells, frequent in late AMD
lesions and in proliferative vitreoretinopathies, might be more
susceptible to increased Cer levels resulting from chronic retina
injuries (Figure 3).
Cer increase is common to several diseases affecting RPE
cells. Excessive acid SMase activation and the subsequent
Cer accumulation have been related to the pathogenic
changes of RPE cells in diabetic retinopathy. High glucose
enhances acid SMase expression, increasing Cer levels in
ARPE19 cells. Interestingly, microRNAs (miR) appear as
novel players in the modulation of sphingolipid metabolic
enzymes. Work from the Busik laboratory showed miR-15a
participates in the regulation of Cer levels; its expression
is decreased by high glucose whereas its overexpression
downregulates acid SMase expression in human RPE cells,
restoring normal Cer levels (Wang et al., 2016). This adds an
additional complexity to the intricate regulation of sphingolipid
metabolism and underscores the usefulness of its modulation in
disease treatment.
Acid SMase activation has been shown in aged RPE and
in a Stargardt disease mouse model, and the consequent
Cer increase impairs autophagic flux, which is crucial for
preserving functional RPE and photoreceptor cells (Toops
et al., 2015). Efficient endolysosome function in RPE is
essential for its phagocytic role and autophagic clearance of
cellular debris, and endolysosomal dysfunction is characteristic
of neurodegenerative diseases. Recent findings show acid
SMase-derived Cer increase and subsequent endolysosomal
dysfunction contribute to internalization of the complement
protein C3, abnormal levels of which have been implicated
in AMD; inhibiting Cer synthesis with desipramine decreases
this dysfunction and C3 internalization (Kaur et al., 2018).
Significantly, epidemiological studies indicate that the use
of tricyclic antidepressants, like desipramine, is associated
with a statistically significant protective effect against
developing early AMD (Klein et al., 2001), emphasizing the
significance of Cer increase in RPE cell dysfunction and AMD
progression (Figure 3).
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Several signaling pathways participate in Cer-induced
RPE cell death. C2-Cer induces the over-production of
ROS, activating the intrinsic apoptotic pathway, with a
subsequent increase in mitochondrial membrane permeability
and caspase-3 activation (Kannan et al., 2004). Both H2O2
and UV radiation induce ER and stress-activated protein
kinase (AMPK) axis, which promote RPE cell death (Yao
et al., 2013). Tunicamycin treatment of cultured RPE cells
induces NF-κB nuclear translocation, increases in nitric oxide
synthase 2 expression and nitrotyrosine formation leading to
cell death, which is prevented with a neutral SMase inhibitor,
implying Cer generation is involved in this death (Kucuksayan
et al., 2014). These data suggest a key role for ER-stress
induced by Cer in RPE cell death and a disease-specific
activation of SMases.
Taking together the above studies, Cer distinctly emerges as
a common pathological mediator in numerous retinopathies of
diverse etiologies, activating multiple downstream pathways that
induce both the degeneration of rod and cone photoreceptors
and RPE dysfunction and death. Pharmacological interventions
to prevent Cer increase might provide useful tools for treating
multiple retinopathies, in a disease-independent mode. The
preservation of retina morphology and functionality by the
inhibition of Cer synthesis (Strettoi et al., 2010; Stiles et al., 2016)
sustains this proposal. In addition, DHA provides an exciting
“proof of concept,” emerging as a modulator of several
enzymes of sphingolipid metabolism in order to prevent Cer
accumulation, thus tilting the sphingolipid rheostat toward cell
survival (Figure 4).
SPHINGOSINE, A DEADLY MESSENGER
IN THE RETINA?
Sph Biological Functions
The finding that Sph inhibits protein kinase C was one of
the first supporting a role for sphingolipids in cell signaling
(Hannun and Bell, 1989; Merrill et al., 1989). Later work
demonstrated that in addition to this modulatory function, Sph,
as its precursor Cer, is a crucial signal for cell death. Sph
levels increase during the early stages of cell death, and its
addition can trigger this death (Cuvillier, 2002). Oxidative stress,
radiation and chemotherapy enhance Cer and Sph generation
promoting senescence, cell cycle arrest or cell death (Ogretmen
and Hannun, 2004; Hannun and Obeid, 2018). Although Sph
increase might result from a decreased SphK activity, as occurs
in radiation-resistant prostate cancer cells (Nava et al., 2000),
the rapid deacylation of Cer is the main source of Sph increase.
The increase in Cer usually precedes that of Sph, suggesting
that Cer hydrolysis by ceramidases gives rise to this increase
(Ohta et al., 1995; Cuvillier et al., 2000). Precisely, the fact
that Cer can be hydrolyzed to Sph, and Sph reacylated to
generate Cer made it difficult initially to discern their effects.
However, exogenous Sph induces apoptosis in cell lines such
as Jurkat cells and rhabdomyosarcoma cell lines even when its
conversion to Cer is inhibited (Cuvillier et al., 2000; Phillips
et al., 2007) and Sph has been shown to act independently from
Cer and at an earlier step in the apoptotic pathway in human
leukemic cells (Sweeney et al., 1996). Conversely, inhibiting the
synthesis of Sph reduces the induction of apoptosis by different
stimuli (Lépine et al., 2004; Suzuki et al., 2004). Sph is now
an established second messenger, rapidly generated by different
apoptotic stimuli to induce cell death. Sph signals this death
through mitochondrial membrane permeabilization, formation
of ROS, cytochrome c release, and caspase-3 activation (Sweeney
et al., 1996; García-Ruiz et al., 1997; Cuvillier et al., 2000, 2001).
Mitochondrial permeabilization is crucial for Sph induction
of cell death; Sph induces the downregulation of Bcl-2 levels
(Sweeney et al., 1996) whereas Bcl-xl overexpression prevents
the onset of apoptosis in spite of the increase in Sph levels
(Cuvillier et al., 2001).
Sph Functions in the Retina
Scarce information exists regarding Sph roles in the eye
(Table 1). Initial data in Drosophila mutants showed that
expression of ceramidase suppresses retinal degeneration in
arrestin mutant flies, in parallel to a decrease in Cer levels;
however, these mutants show enhanced degeneration of
photoreceptors when they are raised with a Sph-enriched diet,
suggesting that Sph is not involved in preventing degeneration
(Acharya et al., 2003).
Sph functions in mammalian retina are still ill-defined. Sph
induces cell death in amacrine and photoreceptor neurons in
culture (Abrahan et al., 2010); oxidative stress rapidly enhances
Sph synthesis, preceding the onset of photoreceptor death
in vitro. In turn, inhibition of Sph synthesis by blocking Cer
breakdown with an alkaline ceramidase inhibitor, MAPP,
markedly decreases oxidative stress-induced photoreceptor
death. Moreover, exogenous Sph promotes photoreceptor
death, even when Cer synthesis is inhibited, implying that
Sph is responsible for this death. As reported in different
cell types, Sph promotes apoptotic death by inducing
mitochondrial permeabilization in photoreceptors, increasing
ROS formation and cytochrome c release, whereas inhibiting
Sph synthesis prevents mitochondrial permeabilization
(Abrahan et al., 2010).
As occurs with Cer (German et al., 2006), DHA prevents Sph-
induced apoptosis, enhancing the expression of SphK1 and its
translocation to the plasma membrane (Miranda et al., 2009;
Abrahan et al., 2010). Noteworthy, inhibition of SphK1 activity
with DHS blocks DHA protection, implying that the decrease in
the levels of Sph and/or the generation of S1P are required for
DHA protective effect (Abrahan et al., 2010). As a whole, these
findings suggest that oxidative stress increases the generation
of Cer and Sph in retina photoreceptors, which act as second
messengers, inducing mitochondrial dysfunction and increased
generation of ROS (Rotstein et al., 2010), to activate cell death.
Lowering Sph levels, by preventing its synthesis or promoting
its phosphorylation to S1P effectively prevents photoreceptor
death, accentuating the relevance of manipulating sphingolipid
metabolism in photoreceptor survival.
Whether Sph acts as a deadly messenger promoting
degenerative changes in other retinal cell types is still unclear.
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In acid SMase knockout mice, increased levels of Sph and
normal levels of Cer are found in the retina (Wu et al., 2015),
probably due to compensatory changes in the activities of other
sphingolipid enzymes, aimed at maintaining Cer levels constant.
These mice show age-dependent retina degeneration and RPE
alterations, with an impaired autophagic flux (Wu et al., 2015);
it still remains to be defined whether Sph increase leads to
these changes. Puzzlingly, overexpression of acid ceramidase
in ARPE19 cells increases their Sph levels, and protects these
cells from oxidative stress, with no concomitant increase in
S1P levels (Sugano et al., 2018). Hence, much remains to be
investigated regarding Sph actions in the retina in order to
design new therapies through the adequately modulation of
sphingolipid levels.
SPHINGOSINE-1-PHOSPHATE, A
FORMIDABLE DOUBLE-EDGED SWORD
IN THE RETINA
S1P Synthesis
Sphingosine-1-phosphate is a crucial lipid intermediate in the
complex sphingolipid metabolism. It has a polar head group
(phosphate), and a long-chain sphingoid base backbone (Sph)
(Saba and Hla, 2004; Figure 1). Sph is phosphorylated to generate
S1P by two different SphKs, SphK1 and SphK2 (Maceyka et al.,
2005; Figure 2). SphK1 is found mainly in the cytosol, close to
the cell membrane, in nearly every cell type. When activated,
it translocates to the plasma membrane, where Sph is localized.
Its structure, functions and roles in disease are widely identified.
Much less is known on SphK2; predominantly localized in
nuclei and mitochondria, its expression is tissue and time of
development dependent (Hait et al., 2009; Strub et al., 2011).
Its structure, functions and the processes in which it is involved
are poorly understood. Its most recognized function is its ability
to phosphorylate FTY720/Fingolimod, a Sph analog and the
first oral pro-drug to be approved for the treatment of multiple
sclerosis by the FDA.
S1P as an Intracellular and an
Extracellular Messenger
Notably, in spite of being chemically identical, S1P molecules
from nuclei or cytoplasm perform different functions. While
nuclear S1P works as a histone deacetylase (HDAC) inhibitor
to epigenetically regulate gene transcription (Hait et al., 2009),
cytoplasmic S1P acts as a second messenger or as an extracellular
ligand. To function as an extracellular ligand, the S1P produced
inside the cell is exported by specific transporters, such as Spinster
2 (Spns2) (Osborne et al., 2008; Kawahara et al., 2009; Spiegel
et al., 2019) or ABCA1 (Sato et al., 2007), ABCC1 (Mitra et al.,
2006), and ABCG2 (Takabe et al., 2010). Once outside the cell,
S1P acts in a paracrine or autocrine fashion, a process known
as “inside-out signaling” (Takabe et al., 2008). As an extracellular
ligand, S1P interacts with five S1P G protein-coupled membrane
receptors (S1PRs), termed S1P1−5. Most cells express one or
more subtypes of S1PRs, and depending on the G-protein
they are coupled with, S1PRs exhibit unique properties and
regulate different cellular processes. Downstream effectors of
S1PRs include adenylate cyclase, PI3-kinase, phospholipase C,
protein kinase C and intracellular calcium (Hla et al., 2001;
Spiegel and Milstien, 2002). In addition, S1P has been proposed
to signal through S1PRs, in a paracrine fashion, upregulating the
transcription of SphK1 and thus activating the S1P/SphK1 axis;
this “outside-in” signaling pathway has been shown to contribute
to the progression of diabetic retinopathy (Huang et al., 2014).
Sphingosine-1-phosphate is a pleiotropic bioactive lipid
mediator; its cellular concentration responds to different stimuli
and is tightly regulated. Concentrations of S1P in blood and
lymph are actually higher than in tissues (Cyster and Schwab,
2012; Olivera et al., 2013; Nagahashi et al., 2016). The final
concentration of S1P in any tissue depends on the balance
between its synthesis and its degradation, with S1P degrading
enzymes playing an important role in maintaining the low tissue
levels of S1P. The main enzymes that degrade S1P are S1P
lyases and SPP. SPP has two isoforms, SPP1 and SPP2, which
catalyze the reversible dephosphorylation of S1P, generating
Sph that it is then converted to Cer by CerS (Mandala, 2001;
Pyne et al., 2009). S1P lyases are responsible for irreversibly
degrading S1P to hexadecenal and ethanolamine-1-phosphate,
removing S1P from the sphingolipid metabolic routes and
providing the only escape path from this complex metabolism
(Bandhuvula and Saba, 2007).
Sphingosine-1-phosphate induces a wide spectrum of
cellular effects, including proliferation, differentiation, survival,
migration, angiogenesis and immune responses (Tabasinezhad
et al., 2013). These pleiotropic effects grant S1P a key role in
several diseases, including cancer, inflammation, autoimmunity,
atherosclerosis and fibrotic disorders (Knapp, 2011; Maceyka
et al., 2012; Takuwa et al., 2013). The highly conserved relevance
of S1P and its regulation of important biological functions in
organisms ranging from yeast and plants to flies and vertebrates
highlight its significance in cell signaling.
The role of S1P in immune functions is well demonstrated,
being involved in infections, allergy and chronic inflammation
(Aoki et al., 2016). Its key role in neuroinflammation is
evident in the successful use of FTY720 in the treatment of
multiple sclerosis. S1P acts as an “extracellular siren song,” its
high plasma concentrations stimulating pathogenic lymphocyte
migration and promoting their egress from lymph nodes to
blood vessels (Bandhuvula and Saba, 2007). FTY720, and more
precisely its phosphorylated form, is a functional antagonist of
almost all S1PRs, excepting S1P2, and prevents S1P activation
of S1P1 by binding and promoting its internalization and
further degradation, thus decreasing S1P1 membrane levels and
retaining lymphocytes in the lymph nodes (Paugh et al., 2003;
Brinkmann et al., 2010; Chun and Hartung, 2010). In addition,
FTY720 has been shown to inhibit de novo synthesis of Cer
(Berdyshev et al., 2009) and histone deacetylases (Hait et al.,
2014). Its efficacy in the treatment of multiple sclerosis has led
to an accelerated research on its therapeutic effects in other
inflammatory diseases.
Glial cells are key players in neuroinflammation and S1P
induces this inflammation in the different glial types (microglia,
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astrocytes, and oligodendrocytes). S1P has been linked to
microglial activation; S1P addition to cultured microglial cell
lines increases the release of pro- inflammatory cytokines
whereas microglial activation in vivo increases SphK1 activity
(Nayak et al., 2010; Lv et al., 2016). Astrocytes, which are
involved in many central nervous system pathologies, respond
to and release inflammatory mediators, and an active crosstalk
exists between S1P and these mediators; S1P induces astrogliosis,
whereas IL-1 induces SphK1 expression (Sorensen et al., 2003;
Paugh et al., 2009). S1P1 expression in astrocytes is critical in the
development of animal models of multiple sclerosis, as shown by
the protective effect of FTY720 (Choi et al., 2011).
Inflammation, angiogenesis, proliferation and migration are
common features in most retinopathies; hence, S1P signaling
of these processes makes it an ideal candidate to regulate
the onset and progression of these diseases. We will here
discuss current knowledge regarding the role of S1P in eye and
retina development and during retina pathological disorders,
particularly the opposing functions of S1P in both neuronal
survival and inflammation and fibrosis in the retina.
S1P, Dr. Jekill or Mr. Hyde in the Retina?
Numerous findings during the last decade have shed new light
on S1P functions in the retina (Table 2). SphK1 is expressed in
photoreceptors whereas SphK1 and SphK2 are expressed both in
ARPE19 and in human fetal RPE cells, implying these cells have
the molecular machinery required for S1P synthesis (Abrahan
et al., 2010; Zhu et al., 2010). A recent work has dissected the
distribution of SphKs and S1PRs in mouse retina (Porter et al.,
2018). SphK1 is low in most mouse ocular tissues and highest
in the retina and optic nerve, whereas higher levels of SphK2 are
observed in all mouse eye tissues. Interestingly, both SphK2 and
SphK1 increase in the retina during early development, peaking
at adulthood. S1p1 and S1p3 are expressed in the retina, while
expression of S1p2 and S1p5 is minimal; S1P3 expression remains
high and constant during retina development, whereas S1P1
increases gradually. Photoreceptors express both S1P1 and S1P3;
S1P1 is highly expressed in RPE cells while S1P3 is localized in
ganglion cells (Porter et al., 2018). Müller glial cells also show
expression of SphK1 and S1P3 (Simón et al., 2015). Hence, the
enzymes and receptors that take part in S1P signaling pathway
are present in most retina cell types.
S1P in Eye Development and Neuronal Survival
Sphingosine-1-phosphate has essential functions during normal
eye development. Mutations in Spns2 cause the abnormal fusion
of eyelids during rat embryogenesis, which can be reversed by
treatment with S1P (Bian et al., 2018). Functional SPNS2 is
crucial for retinal morphogenesis, since dysfunctional SPNS2
causes delayed cell-cycle exit of retinal progenitors and retinal
laminar disorganization (Fang et al., 2018). A role for S1P
signaling in axon guidance has also been reported; S1P promotes
repulsive turning and collapse of growth cones from ganglion
cell axons in the Xenopus retina, through activation of the
S1P5 and RhoA whereas loss of S1P function results in target
recognition errors (Strochlic et al., 2008). S1P is also involved in
signaling in inner retina cells; S1P increases cytosolic Ca2+ levels
in cultured amacrine cells, through the activation of S1P1 and
S1P3 (Crousillac et al., 2009).
Sphingosine-1-phosphate displays a vital function in
preventing neuronal death during retinal injuries. S1P1
contributes to survival and axonal sprout of injured retinal
ganglion cells after damage to the optic nerve (Joly and Pernet,
2016) and FTY720 has neuroprotective effects in experimental
glaucoma in rats (You et al., 2014). Moreover, the expression of
SphK1, S1P2, and S1P3 immediately increases in light-stressed
retinas, with S1PRs localizing to the pyknotic nuclei, suggesting
the up-regulation of a cytoprotective S1P signaling to counteract
the onset of apoptosis (Porter et al., 2018).
S1P as a Mediator in Photoreceptor Survival and
Differentiation
Sphingosine-1-phosphate emerges as a pleiotropic mediator
for development and survival of photoreceptors. Our group
established that 1 µM S1P promotes the proliferation of retinal
progenitors and their later differentiation into photoreceptors;
S1P increases the expression of specific photoreceptor proteins,
and advances the development of rudimentary OS (Miranda
et al., 2009). We also evidenced that S1P is a key mediator in
photoreceptor survival, preventing photoreceptor death during
development in vitro and when exposed to oxidative stress
(Miranda et al., 2009; Rotstein et al., 2010).
An increase in S1P intracellular levels protects 661W cells
from oxidative stress; exogenous addition of S1P or inhibiting
S1P lyase with THI preserves viability in these cells when treated
with H2O2, by decreasing Cer levels, activating the Nrf-regulated
antioxidant pathway and increasing the Bcl-2/Bax ratio (Fabiani
et al., 2017). Further evidence supports the proposal that S1P
is an intracellular second messenger, the synthesis of which is
promoted by photoreceptor trophic factors to exert its actions.
GDNF promotes the proliferation of photoreceptor progenitors
(Politi et al., 2001; Insua et al., 2003), as S1P does, and inhibiting
SphK1 with DHS blocks GDNF mitogenic effect (Miranda et al.,
2009). Inhibition of SphK1 abolishes DHA neuroprotection of
photoreceptors during oxidative stress-induced apoptosis and
DHA enhancement of photoreceptor differentiation (Miranda
et al., 2009; Abrahan et al., 2010). Cytokines and growth factors,
such as Transforming growth factor β and Nerve growth factor
(NGF), enhance the expression of SphK1 and promote its
rapid translocation and activation to increase the synthesis of
S1P, which then acts as a second messenger to exert their
effects (Toman et al., 2004; Yamanaka et al., 2004; Wattenberg
et al., 2006). Noteworthy, both GDNF and DHA upregulate the
expression of SphK1 and promote its translocation to the plasma
membrane (Abrahan et al., 2010). Thus, GDNF and DHA might
elicit their biological effects on photoreceptors by promoting
SphK1 activity and increasing the synthesis of S1P, which then
acts as a second messenger, essential for proper development
and survival of photoreceptors. As described above, DHA
prevents photoreceptor death by promoting Cer glucosylation
(German et al., 2006). As a whole, these findings highlight the
importance of the “sphingolipid rheostat” and of manipulating
sphingolipid metabolism to promote photoreceptor survival in
retinal degenerations (Figure 4).
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TABLE 2 | Functions of Sphingosine-1-phosphate and Ceramide-1-phosphate in the retina.
Sphingolipid Retinal Process
Sphingosine-1- phosphate (S1P) Normal Eye development and function
↓ in Spns2 expression causes abnormal eyelid fusion (Bian et al., 2018), alterations in retinal progenitors cell cycle and laminar
disorganization (Fang et al., 2018)
↑S1P promotes proliferation of retinal progenitors and their later differentiation into photoreceptors (Miranda et al., 2009)
↑ S1P promotes Ca2+ signaling in amacrine cells in the inner retina via S1P1 and S1P3 (Crousillac et al., 2009)
Protection against Retinal injuries
↑ S1P through S1P1 promotes neuronal survival and axonal sprouting after optic nerve damage (Joly and Pernet, 2016)
FTY720 has neuroprotective effects in rat models of glaucoma (You et al., 2014)
↓ S1P abolishes DHA–mediated protection of cultured photoreceptors from oxidative stress (Abrahan et al., 2010)
Light- stressed retinas ↑ expression of SphK1, S1P2 and S1P3 (Porter et al., 2018)
Eye inflammation
↑ S1P promotes retinal angiogenesis and neovascularization (Eresch et al., 2018)
↑ S1P increases IL-8 secretion in RPE (Qiao et al., 2012)
TNF-α promotes ↑ S1P and IL-8 and IL-6 production (Qiao et al., 2012)
↑ S1P promotes VEGF and HIF-1α production in RPE (Terao et al., 2017)
↑ levels of S1P1 and S1P lyase in vitreous of patients with proliferative diabetic retinopathy (Abu El-Asrar et al., 2014)
Retinal fibrosis
S1P promotes proliferation, myofibroblast transformation and formation of pro- fibrotic proteins in RPE cells (Swaney et al.,
2008)
S1P promotes glial migration (Simón et al., 2015)
Blockade of S1P with monoclonal antibodies reduces angiogenesis and sub-retinal fibrosis (Caballero et al., 2009) and prevents
excessive scarring in animal models of glaucoma (Lukowski et al., 2013)
Cer-1- phosphate (C1P) Signaling in photoreceptors
C1P regulates lipid metabolism in photoreceptor outer segments (Pasquaré and Giusto, 2008; Pasquaré et al., 2008)
C1P increases the proliferation of photoreceptor progenitors in retina neuronal cultures (Miranda et al., 2011)
C1P promotes differentiation and prevents apoptosis in cultured rat retina photoreceptors (Miranda et al., 2011)
↑ C1P levels in uveitis (Wang et al., 2018)
Phototransduction
CerK regulation of Cer levels required for phospholipase C activity and PIP2 production during phototransduction (Dasgupta
et al., 2009)
S1P Signaling in Retina Inflammation and
Neovascularization
Sphingosine-1-phosphate is a potent mediator in the modulation
of inflammatory responses and angiogenesis. It is crucial in
the regulation of lymphocyte traffic, an essential step in the
pathology of inflammation (Aarthi et al., 2011; Aoki et al.,
2016). Several cytokines and chemokines, including TNF-α and
interleukin 1-beta (IL1-β), activate SphK1 to produce S1P, which
later induces cyclo-oxygenase 2 activity (Snider et al., 2010).
Collective evidence supports the relevance of S1P in retina
inflammatory and vascular diseases. Abnormal retina blood
vessel growth and macular edema are major complications
leading to vision loss in diabetes retinopathy and S1P emerges
as a key signal in the induction of neovascularization and in
the preservation of retina endothelial barrier integrity (Allende
and Proia, 2002; McGuire et al., 2011). In transgenic mice that
overexpress SphK2, higher retinal S1P concentration accelerates
retinal angiogenesis and increases neovascularization (Eresch
et al., 2018). In turn, downregulation of S1P signaling with
anti-S1P monoclonal antibodies and in S1P2 null mice in
an ischemia-driven retinopathy markedly reduces pathologic
neovascularization (Skoura et al., 2007; Caballero et al., 2009).
RPE cells express the five S1PRs, and exogenous S1P induces the
secretion of Interleukin-8 (IL-8); interestingly, supplementation
with TNF-α enhances S1P3 expression, with a subsequent
increase in S1P-induced IL-8 and IL-6 production (Zhu et al.,
2010; Qiao et al., 2012). S1P also promotes the expression of
vascular endothelial growth factor (VEGF) and hypoxia inducible
factor-1α in RPE cells, which are crucial angiogenic factors
(Terao et al., 2017). A significant increase in the expression
of S1P1 and S1P lyase is detected in the vitreous of patients
with proliferative diabetic retinopathy (Abu El-Asrar et al., 2014)
whereas S1P signaling through S1P1/S1P3 promotes angiogenesis
in vitro, participating in the changes affecting pericytes and
endothelial cells (Durham et al., 2015). Hence, S1P signaling
through S1PRs is a driving force in the onset and progression of
inflammatory and angiogenic responses in retina inflammatory
diseases (Figure 3).
S1P and Retinal Fibrosis
Fibrosis is a pathological process characterized by the
deregulation of production and deposition of extracellular
matrix components, leading to the destruction of normal tissue
function and architecture (Wynn, 2007). Initiated by an acute
injury or a vascular damage that leads to the recruitment of
inflammatory cells, subsequent secretion of pro-inflammatory
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cytokines, as tumor growth factor (TGF)-β, platelet derived
growth factor (PDGF), connective tissue growth factor, IL-3 and
also S1P conducts to the excessive production and deposition of
extracellular matrix components (Kisseleva and Brenner, 2008).
Although the initial damage promotes a physiological fibrotic
response to accomplish tissue repair, the chronic exposure to
irritation and/ or inflammation leads to the formation of a
fibrotic scar that impairs functionality. Many reports establish
the role of S1P in fibrotic disorders in lung (Kono et al.,
2007; Milara et al., 2012), kidney (Geoffroy et al., 2005; Awad
et al., 2011), liver (Davaille et al., 2002; Li et al., 2011; Liu
et al., 2011) and heart (Gellings Lowe et al., 2009; Pchejetski
et al., 2012). However, S1P involvement in retinal fibrosis is
poorly understood.
Many retinal diseases, including AMD, diabetic retinopathy
and proliferative vitreoretinopathy, have a common underlying
etiology of pathological scar tissue production and the role
of TGF-β and PDGF in the development of eye fibrosis is
well-known (Connor et al., 1989; Gamulescu et al., 2006; Saika,
2006; Lei et al., 2007). Recent data indicate a crosstalk between
S1P and TGF-β in human corneas and orbital connective tissues
and suggest that S1P anti- or pro-fibrotic functions in the eye are
tissue-specific (Ko et al., 2017; Nicholas et al., 2017).
The available evidence suggests that S1P is involved in
retina fibrotic disorders. A monoclonal anti-S1P strategy
reduces sub-retinal fibrosis in a mouse model of choroidal
neovascularization and prevents the formation of excessive
scarring after surgery in animal models of glaucoma (Caballero
et al., 2009; Lukowski et al., 2013). Müller glial cells and RPE
cells, the two main cell types that support normal retinal function,
have protagonic roles in the development of retinal fibrosis
(Saika et al., 2008; Bringmann and Wiedemann, 2009). S1P
promotes proliferation, myofibroblast transformation, collagen
production and pro-fibrotic protein expression in human RPE
cells (Swaney et al., 2008). We have shown that S1P has
a key role in the regulation of Müller glial cell motility;
5 µM S1P promotes the migration of cultured rat Müller
glial cells through activation of S1P3 while inhibiting S1P
synthesis using SphK inhibitor 2 (SphKI 2) completely blocks
this migration (Simón et al., 2015). We have proposed that
Müller glial cells release S1P, which signals through S1P3 and
activates the PI3K and the ERK/MAPK pathway to enhance
migration (Simón et al., 2015). Taking into account that the
deregulation of glial migration is involved in proliferative
retinopathies, the S1P/SphK1/S1P3 axis emerges as a key target
for controlling these diseases.
The above findings position S1P as a real Jekill and
Hyde in the retina. S1P is indispensable for establishing
retina structure, regulating proliferation of retinal progenitors
and their later laminar distribution in the retina (Miranda
et al., 2009; Fang et al., 2018). It is also a pro-survival
factor for neurons, promoting their differentiation, preserving
normal functioning and granting neuroprotection (Crousillac
et al., 2009; Miranda et al., 2009; Abrahan et al., 2010; Joly
and Pernet, 2016; Porter et al., 2018). On the other hand,
S1P unleashes threatening processes in Müller glial cells and
RPE cells, such as secretion of pro- inflammatory cytokines,
proliferation, migration and transdifferentiation that promote
and/or enhance inflammation and fibrosis (Swaney et al., 2008;
Qiao et al., 2012; Simón et al., 2015; Terao et al., 2017).
Thus, S1P facilitates the formation of gliotic scars that
alter retinal structure and enhance visual dysfunction instead
of preventing it.
The central role of S1P in the regulation of the crucial cellular
processes that are altered in retinal pathologies turns it into
an exceptional therapeutic target for treating these diseases.
In order to accomplish this goal, several questions remain to
be answered. How to take advantage of S1P protective role
on photoreceptors and simultaneously elude the potentially
risks for visual function derived from its effects on glial and
epithelial cells? The S1P concentration might provide a clue, since
the concentration that protects photoreceptors is 5-fold lower
than that enhancing glial migration; promoting a controlled
intracellular synthesis of S1P and preventing its release might
preclude S1P deleterious effects.
Whether S1P dual roles depend on the signaling pathways
it activates in each cell type and whether they respond to the
microenvironment and/ or the type of injury cells are exposed
to are pending questions as well. An attractive hypothesis for
the dual role of S1P in retina degeneration is its function as
a DAMP, signals that are exposed or released from stressed
cells and recognized by and mobilize the immune system.
S1P and Cer have been proposed as DAMPs in cancer cells;
treating squamous carcinoma cells by photodynamic therapy
results in Cer and S1P increases on the cell surface and in
S1P release, and both sphingolipids trigger NFκB signaling
in macrophages in co-culture (Korbelik et al., 2014). The
ubiquitous expression of S1PRs in macrophages supports this
proposal (Fischer et al., 2007). Recent research has shown that
apoptotic cells release exosome-like vesicles, the biogenesis of
which depends on S1P/S1PRs signaling; these vesicles have
S1P, S1P1, and S1P3 and induce genes of proinflammatory
cytokines and chemokines (Park et al., 2018), highlighting a new
pathway for S1P in the pathogenesis of inflammatory diseases.
Microglia, as resident retinal macrophages, has a detrimental
role and contributes to retinal degeneration; microglia release
of harmful factors contributes to Müller glial cell reactivity
in rd10 mice (Peng et al., 2014; Zhao et al., 2015). DAMPs
have dual roles in the retina; e.g., fractalkine, which has been
reported as a DAMP, is neuroprotective in rd10 retinas by
signaling through its CX3CR1 receptor, preventing microglia-
induced damage (Roche et al., 2016). Stressed photoreceptors
release DAMPs early in degeneration to induce neuroprotective
responses in retinal glial cells by interacting with receptors
as Toll-like receptor 2, a DAMP receptor that increases in
Müller glial cells during degeneration (Hooper et al., 2018).
S1P promotes migration in Müller glial cells and RPE cells
(Swaney et al., 2008; Simón et al., 2015), which might release
it to the retina milieu to act as an autocrine signal and
promote a fibrotic process and/or to act as a paracrine signal in
photoreceptors, promoting neuroprotection. Whether S1P is a
DAMP released by retinal cells to either promote inflammation
or neuroprotection is an exciting question to be explored in the
sphingolipid field.
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Finding answers to these questions would provide crucial
understanding of the puzzling behavior of S1P and new insight
to design effective therapeutic for the treatment of retinopathies.
SEARCHING FOR
CERAMIDE-1-PHOSPHATE FUNCTIONS
IN THE RETINA
C1P Synthesis and Functions
Ceramide-1-phosphate is a later incorporation to the
sphingolipid family, now established as a pleiotropic bioactive
sphingolipid with multiple cellular roles. CerK was first identified
in brain synaptic vesicles and shown to synthesize a molecule
identified as C1P (Bajjalieh et al., 1989). C1P existence and
its synthesis from Cer were then demonstrated in the human
pro-myelocytic leukemia cell line HL-60 (Dressler et al., 1992).
Cer phosphorylation by CerK is the only mechanism for C1P
generation established in mammals, although the presence
of a small pool of C1P in CerK-/CerK- mutants suggests an
alternative biosynthetic mechanism must exist (Bornancin,
2011). C1P is synthesized in the trans Golgi and a specific C1P
transfer protein transports it to the plasma membrane, where
it can be released for autocrine or paracrine signaling (Lamour
et al., 2007; Simanshu et al., 2013). CerK is present in the brain
and brain synaptic vesicles (Bajjalieh et al., 1989; Bajjalieh and
Batchelor, 2000; Hannun et al., 2001) whereas cerebellar granule
cells generate C1P from newly synthesized Cer, formed through
SM degradation and Sph recycling (Riboni et al., 2002).
First thought as an intermediate in the complex sphingolipid
metabolism, C1P functions began to be unraveled when it was
shown to promote proliferation, in fibroblasts and macrophages
(Gomez-Muñoz et al., 1995, 1997; Gangoiti et al., 2008),
myoblasts and cancer cells (Mitra et al., 2007; Gangoiti et al.,
2008). C1P is now known to be antiapoptotic (Gómez-Muñoz
et al., 2004; Granado et al., 2009), to promote cell migration
in different cell types (Granado et al., 2009; Arana et al.,
2012), and to regulate the production of TNF-α (Lamour
et al., 2011). Although mostly known for its pro-inflammatory
actions, both C1P and CerK have been shown to exert either
pro- or anti-inflammatory actions depending on the cell type
(Presa et al., 2016). C1P has been proposed to be relevant for
cancer progression, promoting tumor cell survival, growth and
migration (Mitra et al., 2007; Rivera et al., 2016).
Ceramide-1-phosphate is also an intracellular and an
extracellular messenger. In most cases, it acts as an intracellular
signal, but it can be released to the extracellular milieu
in specific circumstances or upon cell damage (Boath
et al., 2008; Kim et al., 2012; Schneider et al., 2013). The
Gomez-Muñoz laboratory demonstrated that exogenous
C1P stimulates migration of macrophages independently
of intracellular C1P synthesis by activating a G-protein
coupled membrane receptor for C1P, partially identified and
different from S1PRs (Granado et al., 2009). In contrast, C1P
mitogenic effect on macrophages depends on its action as an
intracellular messenger, as C1P effect can be mimicked by a
photolabile caged-C1P analog, which activates cPLA2, PKCα
and NADPH oxidase, generating ROS that promote proliferation
(Arana et al., 2012).
Ceramide-1-phosphate activates multiple signaling pathways.
To enhance proliferation, C1P activates the PI3K and the
ERK/MAPK pathways, Jun N terminal kinase (JNK), nuclear
factor NF-κB (NF-κB) and glucogen synthase kinase 3 (GSK3)
(Gangoiti et al., 2010). C1P promotes survival of macrophages
in the absence of trophic factors by inhibiting caspases
and blocking Cer synthesis (Gómez-Muñoz et al., 2004;
Granado et al., 2009). Activation of PI3K, NF-κB, increases
in Bcl-2, decreases in Bax levels and inhibition of caspases
9 and 3 also participate in its survival effects (Gómez-
Muñoz et al., 2005; Gomez-Muñoz, 2018). The findings
by the Chalfant laboratory that C1P is a direct activator
of cPLA2 provided the link between this sphingolipid and
inflammation (Pettus et al., 2004). C1P interacts with cPLA2,
promoting its translocation and association to membranes, and
its subsequent activation, producing inflammatory mediators
such as eicosanoids (Lamour et al., 2009; Hoeferlin et al., 2013;
Simanshu et al., 2013).
Mounting evidence points to different roles for C1P in
the nervous system. A 5-fold increase in C1P levels in
the subventricular zone in Huntington disease patients has
been reported, with no associated changes in Cer levels; this
increase might represent a response to the chronic brain
damage in these patients and might either reflect an attempt
at neuroprotection and enhanced neurogenesis or contribute
to neuroinflammation and neurodegeneration (Hunter et al.,
2018). C1P has neuroprotective effects in the nervous system.
Upregulation of CerK by Peroxisome proliferator-activated
receptors protects neurons and astrocytes against Cer-induced
death (Aleshin and Reiser, 2014) and promotes survival of
cochlear hair cells during ototoxicity (Tabuchi and Hara, 2018).
C1P might also be involved in neurotransmitter release; C1P
promotes dopamine release from PC12 cells (Jeon et al.,
2005), which is consistent with the ability of C1P to promote
phagolysosome formation and with CerK presence in synaptic
vesicles (Bajjalieh et al., 1989; Hinkovska-Galcheva et al., 1998).
C1P in the Retina
Little is known regarding C1P and CerK roles in the eye (Table 2).
Pioneer work from Acharya’s group in Drosophila eye revealed
an indirect effect of Drosophila ceramide kinase (DCerK) in
phototransduction. DCerK is an integral membrane protein
that phosphorylates Cer, thus decreasing its levels (Dasgupta
et al., 2009). DCerK mutants show severe photoreceptor
degeneration and do not respond to light. The absence of
DCerK increases Cer levels, and leads to proteolysis of NORPA,
a critical effector of phototransduction. The degradation of
this phospholipase C homolog leads to a consequent loss of
activity, and failure in light signal transduction (Dasgupta et al.,
2009). Thus, modulation of Cer levels by DCerK is essential
for phototransduction. Noteworthy, C1P is involved in light-
dependent regulation of other enzymes of lipid metabolism, such
as diacylglycerol lipase and lipid phosphatases, in photoreceptor
rod OS (Pasquaré and Giusto, 2008; Pasquaré et al., 2008),
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suggesting its role in phototransduction might also extend to the
mammalian retina.
The finding that mutations in a CerKL gene are associated
to a variant of autosomal recessive retinitis pigmentosa (Tuson
et al., 2004), and to Cone-rod dystrophy (Littink et al., 2010;
Birtel et al., 2018) brought huge expectations to the field, as
it associated sphingolipid metabolism and retinal degeneration.
CerKL has been further connected with retinitis pigmentosa
in numerous studies (Auslender et al., 2007; Avila-Fernandez
et al., 2008; Avela et al., 2018). However, the physiological
functions of CerKL and its contribution to degeneration are
still unclear. CerKL has no kinase activity neither on lipids
nor on proteins in spite of having a diacylglycerol kinase
domain (Tuson et al., 2004, 2009; Bornancin et al., 2005) and
it interacts with several calcium sensor proteins in the retina
(Nevet et al., 2012). A targeted deletion of CerKL in mouse
leads to a mild retinal phenotype, with increased gliosis and
mild functional alterations of the ganglion cell layer but no gross
morphological alterations (Garanto et al., 2012). In contrast,
CerKL knockdown causes retinal degeneration in zebrafish, with
failure in the development of photoreceptor OS and increased
apoptosis (Riera et al., 2013). CerKL might have antioxidant
functions in the retina. Its overexpression protects retinal cells
from oxidative stress-induced death, whereas its downregulation
renders cells sensitive to this damage; CerKL deficiency causes
zebrafish retinal degeneration and photoreceptor apoptosis
through increased oxidative damage (Tuson et al., 2009; Li et al.,
2014). CerKL is prominently localized in RPE cells, ganglion
cells, inner nuclear layer and photoreceptor inner segments and
its expression increases in light-stressed retinas (Mandal et al.,
2013). An alteration in OS phagocytosis in a zebrafish CerKL
knockout suggests a role for CerKL in RPE cell phagocytosis,
leading to rod-cone dystrophy (Yu et al., 2017). Recent miRNA
analysis of RPE cells exposed to oxidative stress shows that
CerKL is a target of five altered miRNA (Donato et al., 2018).
Existing evidence thus points to a role for CerKL in retina
protection from oxidative stress-induced damage, and not related
to Cer phosphorylation.
Ceramide kinase is ubiquitously and highly expressed in the
retina (Mandal et al., 2013). CerK−/− retinas show decreased
C1P and increased Cer; on the contrary, CerKL−/− retinas
have normal C1P and Cer levels, supporting CerK as the
major and probably unique responsible for C1P synthesis in
the retina (Graf et al., 2008). RPE cells express CerK, among
other enzymes involved in sphingolipid metabolism (Zhu
et al., 2010) and no C1P is detected in these cells in CerK−/−
retinas (Graf et al., 2008). Our group has shown that exogenous
C1P promotes the proliferation of cultured photoreceptor
progenitors and advances their differentiation as photoreceptors,
enhancing the expression of opsin and peripherin and promoting
the formation of rudimentary OS (Miranda et al., 2011).
Notably, overexpression of CerK inhibits all-trans retinoic acid
(ATRA)-induced differentiation of a human neuroblastoma
cell line, SH-SY5Y (Murakami et al., 2010), suggesting that
the effect of C1P on differentiation might be cell or context
dependent. C1P also stimulates the survival of cultured
photoreceptors, preventing their degeneration; this protection
involves the preservation of mitochondrial potential, suggesting
that C1P activates pathways upstream of mitochondrial
depolarization (Miranda et al., 2011). Consistently, whereas
a pan-caspase inhibitor decreases photoreceptor death in
controls, it promotes no further reduction in photoreceptor
death in C1P-supplemented cultures, suggesting C1P might
prevent caspase activation (Miranda et al., 2011). Inhibiting
the de novo synthesis of Cer prevents photoreceptor cell
death in culture (German et al., 2006). Since C1P prevents
macrophage apoptosis by impeding Cer accumulation, either
by inhibiting its de novo synthesis or acid SMase activity
(Gómez-Muñoz et al., 2004; Granado et al., 2009), C1P might
also block Cer synthesis in photoreceptors, thus promoting their
survival (Figures 3, 4).
Higher levels of C12-, C16- and C24-C1P, and of C16- and
C18-Cer have been found in retinas in a rat model of endotoxin-
induced uveitis, together with increases in TNF-α and IL-6
levels, suggesting these sphingolipids might participate in the
inflammation process (Wang and Bieberich, 2018). Ongoing
work in our laboratory suggests that C1P might promote the
migration of retina Müller glial cells in vitro, which, together with
glial proliferation, contributes to the progression of proliferative
retinopathies (Vera et al., unpublished data).
Ceramide-1-phosphate functions in the retina are just
starting to be uncovered. Existing evidence points to a crucial
role of C1P in photoreceptor functionality, promoting their
proliferation, survival and advancing differentiation. It might also
be involved in modulation of phototransduction. Its contribution
to inflammatory and proliferative pathologies of the retina has to
be further explored.
DIHYDROCERAMIDE, A NEWCOMER
PLAYER IN RETINA CELL DEATH?
Dihydroceramide, the immediate precursor of Cer in the de
novo synthetic pathway, had long been considered as an inactive
sphingolipid, since its exogenous addition had little effect on
cell death (Ahn and Schroeder, 2010). However, cumulative
evidence during the last decade supports a signaling role
for endogenous DHCer and for other dihydrosphingolipids
as well. Its accumulation has been implicated in autophagy
regulation. Noteworthy, DHCer increase has been shown to
induce cytotoxic autophagy in cancer cells and an impairment
of autophagic flux and increase in fibrosis markers in liver cells
(Hernández-Tiedra et al., 2016; Lee et al., 2017). DHCer also
triggers cell cycle arrest and cell death (reviewed in Siddique
et al., 2015). Therefore, it is now thought that DHCer is the
principal Cer-mediated autophagy regulator (Siddique et al.,
2015; Hannun and Obeid, 2018).
In the eye, early work showed distinct effects between Cer and
DHCer. Cer induces cell death in cultured rat photoreceptors
and amacrine neurons, in human RPE cells, in human corneal
stromal fibroblasts and in lens epithelial cells, whereas addition
of DHCer has no deleterious effect in these cell types (Barak
et al., 2001; German et al., 2006; Samadi, 2007; Rizvi et al.,
2011). However, recent evidence suggests a noxious role for
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DHCer in the eye. DHCer content increases during aging in
human lens and might be related to changes in the permeability
barrier properties (Deeley et al., 2010). Both Cer and DHCer
content increase in light-induced photoreceptor degeneration
in albino rats, and preventing these increases protects retinal
function and structure (Chen et al., 2013; Huang et al., 2014).
DHCer desaturase catalyzes the conversion of DHCer to Cer and
its modulation is crucial for the signaling pathways regulated
by both sphingolipids. Loss of DHCer desaturase in Drosophila
eye leads to DHCer accumulation, increased ROS production
and loss of photoreceptor functionality and viability; in turn,
blocking DHCer synthesis preserves their viability (Jung et al.,
2017). Further work will establish whether DHCer is a member
of the club of deadly sphingolipid messengers and whether it
contributes to retinal pathologies.
Unraveling the Sphingolipid Network in
the Retina
Sphingolipids emerge as crucial mediators in the activation of
numerous pathways that might either activate neuroprotective
mechanisms or whose dysregulation might lead to retina
dysfunction. Cer stands out as a key messenger in the onset of
degeneration in photoreceptors induced by oxidative stress and
in numerous models of retina neurodegeneration; its increase
through de novo synthesis or by SM breakdown activates different
downstream pathways leading to cell death. Cer buildup, due to
an activation or increased expression of SMases is also crucial
in the onset of RPE cell death and inflammation. Preventing
Cer increase through the inhibition or modulation of different
enzymes of its intricate metabolism has been shown to effectively
prevent photoreceptor and RPE cell death, both in vivo and
in vitro, and preserve visual function. These findings underscore
both the relevance of imbalances in Cer levels as inducers of RPE
and photoreceptor cell death and the significance of modulation
of the sphingolipid metabolism as a therapeutic strategy for
the treatment of retina neurodegenerations. Having an integral
picture of the functions of Cer in the retina and of the effects
of preventing its accretion demands establishing the processes
regulated by Cer in glial cells and its potential role in their
gliotic response. Several questions remain to be answered in
order to accomplish the fine tuning of the highly interconnected
sphingolipid metabolism, which is crucial for the development
of new treatments for retinal pathologies. The complexity of
this metabolism makes its modulation a powerful approach
for preserving vision function but might also be an Achilles’
heel, jeopardizing strategies based on the inhibition of one of
the metabolic pathways leading to Cer synthesis. Being Cer
the central molecule in sphingolipid metabolism, the effects of
blocking a single pathway established as crucial in generating Cer
accumulation in a particular pathological circumstance should
be explored. This inhibition might efficiently reduce cell death
but impair other key, Cer-dependent, retinal processes or affect
them indirectly, through the increase in bioactive sphingolipid
metabolites. As blocking a certain biosynthetic pathway for
Cer has been shown to provide a transient protection, it is
critical to explore whether altering the flux through the network
activates alternative Cer biosynthetic pathways and/or leads
to the accumulation of bioactive sphingolipids, such as Sph
or DHCer, which might trigger cell death. Further research
aimed at understanding these balances and connections in a
comprehensive molecular way might contribute to devising
successful treatments based in new or already established drugs
or suggest the necessity of combining different drugs in order to
simultaneously modulate these metabolic processes.
Modulation of the sphingolipid rheostat might provide
clues for preventing the death of photoreceptors (Figure 4).
Nevertheless, S1P functions remain enigmatic. S1P, either
exogenous or generated intracellularly, promotes survival of
these cells; notably, photoreceptor trophic factors enhance
S1P synthesis to exert their functions. A pending question is
determining whether increasing S1P intracellular levels, either
by promoting its synthesis and/or or blocking its degradation
can prevent degeneration of photoreceptors and preserve their
functionality in diseased retinas. Even if this is the case, taking
advantage of S1P neuroprotective effect on photoreceptors still
requires uncovering the clues to prevent or overcome S1P
deleterious effects on other retinal cells, as glial, epithelial and
endothelial cells, that may turn on fibrosis, neovascularization
and inflammation. Similarly, the actions of S1P and Cer are
critical for the pathogeneses of proliferative diseases, such as
diabetic retinopathy and AMD. Both sphingolipids drive forward
the crucial events leading to the progression of these diseases,
with S1P inducing fibrosis and pro-inflammatory changes
and Cer triggering cell death. Given the cross-conversions of
sphingolipids, it is necessary to find out how to simultaneously
balance their levels to avoid the onset of lethal processes in the
retina. As stated above, this requires unraveling the intricate
network of metabolic and signaling pathways to obtain the
cues for refining the adjustment of the sphingolipid network.
At least part of these cues might lie in the differential cellular
expression of S1PRs and/or the molecular pathways activated
by S1P. Uncovering the myriad of potential combinations of
S1PRs and downstream signaling pathways, either activatory or
inhibitory, might explain the variety of the responses triggered
by S1P in different retinal cell types. In order to make
use of the S1P axis as a tool for the treatment of retinal
diseases, the precise mechanisms by which S1P achieves its
effects should be clarified. Current evidence suggests that the
expression pattern of S1PRs in the retina is modified in particular
pathologies. Further studies are now required to establish
whether photoreceptors, glial and epithelial cells differ in their
S1PR expression pattern, and if and how are these patterns
differentially modulated in each cell type by the environmental
context, i.e., healthy or diseased retina and by extracellular cues,
such as starvation, light damage, or oxidative stress. In addition,
it is essential to understand the roles of S1P, and also establish
those of C1P, in controlling neovascularization and fibrotic
changes and whether they exhibit pro or anti-inflammatory
actions in different pathological environments. Advancing our
understanding of the multiple roles of sphingolipids and of
the fine detail and regulation of their complex metabolic
network will contribute to achieve much-needed therapies for
retina pathologies.
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